AQST icon

Aquestive Therapeutics

2.38 USD
+0.00
0.00%
At close May 16, 4:00 PM EDT
After hours
2.39
+0.01
0.42%
1 day
0.00%
5 days
-16.49%
1 month
-4.80%
3 months
-24.44%
6 months
-48.71%
Year to date
-35.15%
1 year
-27.44%
5 years
-63.04%
10 years
-85.17%
 

About: Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.

Employees: 142

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

212% more call options, than puts

Call options by funds: $1.89M | Put options by funds: $605K

36% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 33

0% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]

5% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 22

3% less funds holding

Funds holding: 117 [Q3] → 114 (-3) [Q4]

3.79% less ownership

Funds ownership: 51.37% [Q3] → 47.57% (-3.79%) [Q4]

33% less capital invested

Capital invested by funds: $232M [Q3] → $155M (-$77.8M) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$8
236%
upside
Avg. target
$9
278%
upside
High target
$10
320%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Raghuram Selvaraju
38% 1-year accuracy
56 / 149 met price target
320%upside
$10
Buy
Reiterated
15 May 2025
Lake Street
Thomas Flaten
50% 1-year accuracy
2 / 4 met price target
236%upside
$8
Buy
Maintained
7 Mar 2025

Financial journalist opinion

Based on 6 articles about AQST published over the past 30 days

Neutral
Seeking Alpha
3 days ago
Aquestive Therapeutics, Inc. (AQST) Q1 2025 Earnings Call Transcript
Aquestive Therapeutics, Inc. (NASDAQ:AQST ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Brian Korb - IR Dan Barber - CEO Ernie Toth - CFO Sherry Korczynski - SVP of Sales and Marketing Carl Kraus - CMO Conference Call Participants Roanna Ruiz - Leerink Partners David Amsellem - Piper Stanley Kristen Kluska - Cantor Fitzgerald Jason Butler - Citizens JMP Raghuram Selvaraju - HC Wainwright Dennis Resnick - Raymond James Nelson Cox - Lake Street Capital Markets Operator Good day and thank you for standing by. Welcome to the Aquestive Therapeutics First Quarter 2025 Earnings Conference Call.
Aquestive Therapeutics, Inc. (AQST) Q1 2025 Earnings Call Transcript
Neutral
Zacks Investment Research
4 days ago
Aquestive Therapeutics (AQST) Reports Q1 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Aquestive Therapeutics (AQST) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Aquestive Therapeutics (AQST) Reports Q1 Earnings: What Key Metrics Have to Say
Negative
Zacks Investment Research
4 days ago
Aquestive Therapeutics (AQST) Reports Q1 Loss, Lags Revenue Estimates
Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.17 per share a year ago.
Aquestive Therapeutics (AQST) Reports Q1 Loss, Lags Revenue Estimates
Neutral
GlobeNewsWire
4 days ago
Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
WARREN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced financial results for the first quarter ended March 31, 2025, and provided a strategic business update.
Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Positive
Seeking Alpha
1 week ago
Aquestive Therapeutics: Unprofitable For A Few More Years, But Significant Upside Potential
AQST's Anaphylm, a sublingual epinephrine film, shows strong potential with FDA approval expected in Q2'25 and a $1B annual revenue target. AQST's financial health is weaker compared to competitors, with a probable need to raise $100M-$150M in the next 2-3 years. My base-case DCF model estimates a fair value of $8.11, offering a 179% upside, with an optimistic scenario reaching $15.38.
Aquestive Therapeutics: Unprofitable For A Few More Years, But Significant Upside Potential
Neutral
GlobeNewsWire
2 weeks ago
Aquestive Therapeutics to Report First Quarter 2025 Financial Results and Recent Business Highlights on May 12 and Host Conference Call on May 13 at 8:00 a.m. ET
WARREN, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the first quarter ended March 31, 2025 and provide an update on recent developments in its business after market close on Monday, May 12, 2025.
Aquestive Therapeutics to Report First Quarter 2025 Financial Results and Recent Business Highlights on May 12 and Host Conference Call on May 13 at 8:00 a.m. ET
Neutral
GlobeNewsWire
1 month ago
Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium
WARREN, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in the Piper Sandler Spring Biopharma Symposium in Boston. The Aquestive team will host investor meetings at the event on April 17.
Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium
Positive
Seeking Alpha
1 month ago
Aquestive Therapeutics: Oral Anaphylaxis NDA Opportunity Spells Buy
Aquestive currently plays small ball with a handful of approved products that offer no adequate financial potential. Its recently approved Libervant, which offered greater revenue opportunity, is mired in litigation. Aquestive's Anaphylm, which is set for an imminent FDA filing, has blockbuster potential.
Aquestive Therapeutics: Oral Anaphylaxis NDA Opportunity Spells Buy
Neutral
Seeking Alpha
2 months ago
Aquestive Therapeutics, Inc. (AQST) Q4 2024 Earnings Call Transcript
Aquestive Therapeutics, Inc. (NASDAQ:AQST ) Q4 2024 Results Conference Call March 6, 2025 8:00 AM ET Company Participants Brian Korb - IR Dan Barber - CEO Ernie Toth - CFO Sherry Korczynski - SVP of Sales and Marketing Carl Kraus - CMO Conference Call Participants David Amsellem - Piper Sandler Francois Brisebois - Oppenheimer Kristen Kluska - Cantor Fitzgerald Jason Butler - JMP Securities Raghuram Selvaraju - HC Wainwright & Co. Gary Nachman - Raymond James Thomas Flaten - Lake Street Capital Markets James Molloy - Alliance Global Partners Operator Good day, and thank you for standing by. Welcome to the Fourth Quarter 2024 Aquestive Therapeutics Earnings Conference Call.
Aquestive Therapeutics, Inc. (AQST) Q4 2024 Earnings Call Transcript
Positive
Zacks Investment Research
2 months ago
Compared to Estimates, Aquestive Therapeutics (AQST) Q4 Earnings: A Look at Key Metrics
The headline numbers for Aquestive Therapeutics (AQST) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Compared to Estimates, Aquestive Therapeutics (AQST) Q4 Earnings: A Look at Key Metrics
Charts implemented using Lightweight Charts™